| Susan C Hoovler, ARNP | |
|
33 Walker St, Ashland, ME 04732-3429 | |
| (207) 827-6128 | |
| Not Available |
| Full Name | Susan C Hoovler |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 33 Walker St, Ashland, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104028281 | NPI | - | NPPES |
| 1104028281 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | ARNP821072 (Florida) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | CNP81562 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Susan C Hoovler, ARNP 33 Walker St, Ashland, ME 04732-3429 Ph: (207) 945-5247 | Susan C Hoovler, ARNP 33 Walker St, Ashland, ME 04732-3429 Ph: (207) 827-6128 |
News Archive
"New research supported by Sightsavers and the African Programme for Onchocerciasis Control (APOC) shows that yes, onchocerciasis really can be eliminated when treatment is distributed in an area for a sustained period" and "found that the disease may already be eliminated in one Nigerian state, marking a significant milestone for onchocerciasis control programs," the Global Network for Neglected Diseases' "End the Neglect" blog writes.
OrphageniX Inc., a new biotechnology company founded by University of Delaware researchers, has been established in Wilmington to develop and commercialize UD-patented technologies for repairing genes that cause rare, hereditary diseases such as sickle cell anemia and spinal muscular atrophy.
Studies have shown that most of a female's bone mass is built between the ages of 13 and 15 and then slowly lost in the last four decades of her life. Therefore, attaining optimal bone mass and bone strength in adolescence may offer the best protection possible against osteoporosis - bone loss in post-menopausal women and the elderly.
The dead swan found in Fife in Scotland on March 29th has now been identified by DNA tests as one of a migratory species, quelling fears that it was the harbinger of the first outbreak in the UK.
Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS).
› Verified 7 days ago